drugset
drugset / Trial / NCT03617432

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

NCT03617432 ↗

Phase 2 Unknown 114 enrolled Peking University Jiangxi Provincial Cancer Hospital · collabPeking University International Hospital · collabShandong Tumor Hospital · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical Trial

Timeline

Start
2018-08-28
Primary completion
2020-09-30
Completion
2022-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucidinostat Small molecule 15 mg Oral
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Background Etoposide Small molecule 100 mg/m2 Intravenous
Background Prednisone Other / unclassified 100 mg Oral
Background Vincristine Small molecule 1.4 mg Intravenous

Indications

No indication recorded.